Increased preglomerular reactivity, due to reduced nitric oxide (NO) production or increased levels of ANG II and reactive oxygen species (ROS), has been linked to hypertension. Using A1-receptor knockout (A1 Ϫ/Ϫ ) and wild-type (A1 ϩ/ϩ ) mice we investigated the hypothesis that A1-receptors modulate arteriolar and blood pressure responses during NO synthase (NOS) inhibition or ANG II treatment. Blood pressure and renal afferent arteriolar responses were measured in nontreated mice and in mice with prolonged N -nitro-L-arginine methyl ester hydrochloride (L-NAME) or ANG II treatment. The hypertensive responses to L-NAME and ANG II were clearly attenuated in A1 Ϫ/Ϫ mice. Arteriolar contractions to L-NAME (10 Ϫ4 mol/l; 15 min) and cumulative ANG II application (10 Ϫ12 to 10 Ϫ6 mol/l) were lower in A1 Ϫ/Ϫ mice. Simultaneous treatment with tempol (10 Ϫ4 mol/l; 15 min) attenuated arteriolar responses in A1 ϩ/ϩ but not in A1 Ϫ/Ϫ mice, suggesting differences in ROS formation. Chronic treatment with L-NAME or ANG II did not alter arteriolar responses in A1 Ϫ/Ϫ mice, but enhanced maximal contractions in A1 ϩ/ϩ mice. In addition, chronic treatments were associated with higher plasma levels of dimethylarginines (asymmetrical and symmetrical) and oxidative stress marker malondialdehyde in A1 ϩ/ϩ mice, and gene expression analysis showed reduced upregulation of NOS-isoforms and greater upregulation of NADPH oxidases. In conclusion, adenosine A1-receptors enhance preglomerular responses during NO inhibition and ANG II treatment. Interruption of A1-receptor signaling blunts L-NAME and ANG II-induced hypertension and oxidative stress and is linked to reduced responsiveness of afferent arterioles. preglomerular function; hypertension; oxidative stress; tubuloglomerular feedback; reactive oxygen species THE RENAL AFFERENT ARTERIOLE is the effector site of the tubuloglomerular feedback (TGF) mechanism that regulates glomerular perfusion and filtration (43). In this way, TGF contributes to the renal autoregulation and the long-term blood pressure control. Osswald et al. (37) first proposed that TGFinduced afferent arteriolar vasoconstriction may be elicited through local generation of adenosine following increased NaCl transport. Adenosine, via activation of A 1 -receptors, has been demonstrated to mediate TGF responses in both rats (16, 44) and mice (3, 46), whereas activation of A 2 -receptors (A 2A or A 2B ) and nitric oxide (NO) release may attenuate the response (11). Elevated levels of ANG II and reactive oxygen species (ROS) may enhance TGF response and preglomerular reactivity (49, 56) and have been associated with hypertension in several experimental models (5, 6, 34, 48, 56, 57) . There is considerable evidence for a synergistic interaction between ANG II and adenosine in the kidney (17), and this importantly contributes to regulation of the renal microcirculation (28). Although an interaction between ANG II and adenosine was described more than three decades ago (45), the mechanisms of synergism and its role in blood pressure regulation remains incompletely understood. Studies in isolated and perfused afferent arterioles have shown that interaction between adenosine and ANG II potentiates the contractile response (28). Moreover, ANG II has been shown to elevate intrarenal adenosine concentrations, either by increased release (19) or decreased metabolism of adenosine (15) . As yet the role of adenosine A 1 -receptors in development of hypertension is not clear. The aim of this study was to investigate the hypothesis that presence of preglomerular A 1 -receptors contributes to the development of hypertension in models with reduced NO or elevated ANG II levels. This study also extends current knowledge of an interaction between adenosine and ANG II-elicited responses by studying both acute and chronic effects on vascular responses and oxidative stress. Blood pressure and afferent arteriolar responses were studied in adenosine A 1 -receptor knockout (A 1 Ϫ/Ϫ ) and wild-type (A 1 ϩ/ϩ ) mice during baseline, and with chronic treatment with the NO synthase (NOS) inhibitor N -nitro-L-arginine methyl ester hydrochloride (L-NAME) or with ANG II.
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Ϫ/Ϫ
) and wild-type (A 1 ϩ/ϩ ) mice during baseline, and with chronic treatment with the NO synthase (NOS) inhibitor N -nitro-L-arginine methyl ester hydrochloride (L-NAME) or with ANG II.
MATERIAL AND METHODS

Experimental Design
Experiments were conducted on adenosine A1-receptor knockouts (A1 Ϫ/Ϫ ) and corresponding wild-type mice (A1 ϩ/ϩ ) from heterozygous breeding pairs. The strain was developed by Johansson et al. (24) and backcrossed by the Jackson Laboratory (Bar Harbor, ME) to a C57BL/6J background. Genotyping of the offspring was performed by PCR. Both genders were used with equal distribution and similar age (10 -16 wk) in every set of experiments. The animals were fed standardized mouse chow (0.7% NaCl, R36, batch SD389; Lactamin, Kimstad, Sweden) and tap water ad libitum. Telemetric blood pressure measurements, afferent arteriolar experiments, plasma analysis, and gene expression studies were performed in nontreated mice and in those with prolonged L-NAME or ANG II treatment (Fig. 1A) .
Blood Pressure Responses to Prolonged L-NAME and ANG II Treatments
Telemetric devices (PA-C10; DSI, St Paul, MN) were implanted in A 1 Ϫ/Ϫ and A1 ϩ/ϩ mice as previously described (8) . After surgery, the animals were allowed to recover for at least 10 days. Thereafter, the blood pressure was measured continuously for 72 h to determine basal levels. In the first series of experiments, mice were receiving L-NAME in their drinking water (500 mg/l) and blood pressure was measured continuously. In the second series of experiments, mice were anesthetized by spontaneous inhalation of isoflurane (Forene; Abbott Scandinavia, Solna, Sweden) in air (ϳ2.2%) and an osmotic minipump (Alzet, Durect, CA) was implanted subcutaneously, delivering ANG II (Sigma-Aldrich) at 400 ng·kg Ϫ1 ·min Ϫ1 . After implantation, blood pressure was recorded continuously throughout the ANG II delivery period.
Afferent Arteriolar Measurements
Dissection and perfusion of arterioles. The outer cortical afferent arterioles were dissected at 4°C in DMEM (0.1% albumin). Arterioles with their glomeruli were perfused in a thermoregulated chamber (37°C) by a perfusion system, which allowed adjustment of outer holding and inner perfusion pipettes (Vestavia Scientific, Vestavia Hills, AL). The chamber and the perfusion system were fixed to the stage of an inverted microscope (Nikon, Badhoevedorp, The Netherlands). A 5-m diameter perfusion pipette, inserted into the holding pipette, was connected to a reservoir containing the perfusion solution to provide a pressure of 100 mmHg in the pressure head, producing a flow of ϳ50 nl/min. The criteria for the use of an arteriole were a satisfactory, remaining basal tone and an intact myogenic response. Increasing perfusion pressure rapidly and assessing the change in the luminal diameter, which produced a constriction, verified both criteria. A further criterion was a fast and complete constriction in response to KCl (100 mmol/l) solution.
Measurements of arteriolar diameter. The setup for the renal afferent arteriolar experiments is demonstrated in Fig. 1B . The experiments were recorded by a video system, digitized off-line, and analyzed as decribed previously (38) . Changes in luminal diameters were measured to estimate the effect of vasoactive substances. In all series, the last 10 s of a control or treatment period were used for statistical analysis of steady-state responses. The experimental period (15 min) with L-NAME and/or tempol were analyzed every 5th min. The reported 15 min responses to L-NAME or tempol ϩ L-NAME are those obtained before simultaneous application with ANG II. Arterioles used to study ANG II or norepinephrine dose responses alone had not been exposed to any other drug prior to the actual experiment. Each experiment used a separate dissected afferent arteriole, and only one arteriole was used per animal. As previously described (8) , inner luminal diameter and media thickness were measured during baseline (before application of any substances), and the areas were calculated to compute the media-to-lumen ratios to assess vascular remodeling.
Plasma Analysis
Measurement of L-arginine and asymmetric and symmetrical dimethylarginine. Concentrations of arginine, and asymmetric (ADMA) and symmetrical (SDMA) dimethylarginine in plasma were measured with HPLC as described previously (47), using modified chromatographic separation conditions (13) . In brief, solid-phase extraction on polymeric cation-exchange columns was performed after addition of monomethylarginine as the internal standard. After derivatization with orthophtaldialdehyde reagent containing 3-mercaptopropionic acid, analytes were separated by isocratic reversed-phase HPLC with fluorescence detection. For all analytes the intra-and interassay coefficients of variation were Ͻ 1.5% and Ͻ 3.5%, respectively.
Malondialdehyde. Total, i.e., free and protein-bound malondialdehyde (MDA) concentration in plasma was measured in duplicate by HPLC and fluorescence detection after alkaline hydrolysis and reaction with thiobarbituric acid, as previously described (52) . The intrarun and interrun variations were 3.5% and 8.7%, respectively.
Gene Expression in Renal Cortex
mRNA analysis. Infusion of cold PBS was started once the vena cava was cut to remove the blood. The kidneys were explanted, blotted, and weighed. The renal cortex was separated and homogenized in lysis buffer (1.0% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mmol/l NaF, 80 mmol/l Tris, pH 7.5) containing enzyme inhibitors (Complete Mini; 1 tablet/1.5 ml; Roche Diagnostics, Mannheim, Germany). RNA was isolated with RNA-Bee-reagent (Biozol, Eching, Germany) and reverse transcribed with random hexamers (High Capacity cDNA RT-Kit, cat. no. 4374966; Applied Biosystems, Foster City, CA), according to the manufacturer's protocols. Quantitative PCR analysis was performed with a StepOnePlus device (Applied Biosystems, Foster City, CA). SYBR Green was used for the fluorescent detection of DNA generated during PCR. The PCR reaction was performed in a total volume of 12.5 l with 0.4 pmol/l of each primer (Table 1) , and ImmoMix (Bioline, Luckenwalde, Germany): 2 l cDNA corresponding to 20 ng RNA was used as a template. Experiments were performed in triplicate with similar results. The expression levels of mRNA were normalized to ␤-actin by the ⌬Ct-method. Parallelism of amplification curves of the test and control was confirmed.
Drugs and Reagents
DMEM/F12 with 10 mmol/l HEPES (Invitrogen, Lidingö, Sweden) was used for dissection, bath, and perfusion. The pH was adjusted to 7.4 after addition of BSA (SERVA Electrophoresis Heidelberg, Ger- many). The concentration of BSA was 0.1% in dissection and bath solutions, and 1% in the perfusion solution. The K ϩ solution had the composition (in mmol/l): 20 NaCl, 95 KCl, 25 NaHCO 3, 2.5 K2HPO4, 1.3 CaCl 2, 1.2 MgSO4, 5.5 glucose. The drugs used were ANG II, norepinephrine, L-NAME, and 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy (tempol) from Sigma-Aldrich. All drugs were applied to the bath solution in the arteriolar contraction experiments.
Statistical Analysis
Values are presented as means Ϯ SE. Repeated-measures ANOVA was used to test time-or concentration-dependent changes in the arteriolar diameter and to assess differences between the groups. Post hoc comparisons were performed with Fisher's test. ANOVA followed by the Fisher's post hoc test, when appropriate, were used for analysis of blood pressure, vascular remodeling, and plasma concentrations. Wilcoxon tests were applied for gene expression data. Differences were considered to be statistically different if P Ͻ 0.05.
Ethics
The experiments were approved by the Uppsala Ethical Committee for Animal Experiments and conducted in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals.
RESULTS
All animals were in good condition, and at the time of euthanasia there was no difference in body weight between the A 1 Ϫ/Ϫ (29.0 Ϯ 1.0 g; n ϭ 42) and A 1 ϩ/ϩ mice (31.0 Ϯ 1.1 g; n ϭ 42).
Blood Pressure Responses to Prolonged L-NAME and ANG II Treatments
Basal blood pressure (i.e., 3 days mean) was slightly higher in A 1 Ϫ/Ϫ mice (109 Ϯ 3 mmHg; n ϭ 12) than in A 1 ϩ/ϩ mice (101 Ϯ 2 mmHg; n ϭ 12). This is in agreement with previous findings (4), and may be related to somewhat higher renin levels in the knockouts. A 1 Ϫ/Ϫ mice displayed attenuated blood pressure responses to chronic L-NAME treatment (Fig. 2,  A-B) . The mean blood pressure elevation during L-NAME treatment was 14 mmHg in the A 1 ϩ/ϩ mice, but only 4 mmHg in the A 1 Ϫ/Ϫ mice (Fig. 2C) . Prolonged ANG II infusion increased blood pressure to a greater degree in A 1 ϩ/ϩ mice, than observed in A 1 Ϫ/Ϫ mice (Fig. 2, D-E) . In the end of ANG II treatment (days [11] [12] [13] [14] , blood pressure was significantly higher in wild-type mice than in the knockouts (Fig. 2F) .
Afferent Arteriolar Measurements
The basal luminal diameter of afferent arterioles was larger in nontreated A 1 Ϫ/Ϫ mice (10.00 Ϯ 0.52 m; n ϭ 28) than in A 1 ϩ/ϩ mice (8.55 Ϯ 0.42 m; n ϭ 28) (P ϭ 0.03). Analysis of media-to-lumen ratios showed that A 1 -receptor deficiency was not associated with any significant changes in preglomerular structures compared with A 1 ϩ/ϩ mice ( Table 2) . Neither chronic L-NAME nor ANG II treatment influenced vascular properties within genotype, as media and luminal area, as well media-to-lumen ratio were not significantly different. However, with chronic L-NAME and ANG II treatment, media-to-lumen ratios tended to be higher for A 1 ϩ/ϩ compared with A 1 Ϫ/Ϫ mice (P ϭ 0.09 and 
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p67Phox-fw 5=-AAG ACC TTA AAG AGG CCT TGA CGC A-3= p67Phox-rev 5=-TCG GAC TTC ATG TTG GTT GCC AA-3= 0.10, respectively). To control for differences in baseline luminal diameter, results are presented for both absolute changes (m) and fractional changes (%) of the vessels. Arterioles from both genotypes displayed a fast and complete constriction in response to KCl (data not shown). Arteriolar contractions in nontreated mice. EFFECT OF ANG II. Concentration response curves were obtained by cumulative application of ANG II (10 Ϫ12 to 10 Ϫ6 mol/l; each dose applied for 2 min). ANG II constricted afferent arterioles from A 1 ϩ/ϩ mice in a concentration-dependent manner, with a maximum response of 41%. Afferent arterioles of A 1 Ϫ/Ϫ mice were less responsive, with a maximum contraction of 18% to ANG II (Fig. 3A) .
EFFECT OF L-NAME TREATMENT ON ANG II-INDUCED CONTRACTIONS.
To investigate the role of NO in offsetting ANG II-induced arteriolar contraction, vessels were treated with L-NAME (10 Ϫ4 mol/l) for 15 min before and during treatment with ANG Ϫ/Ϫ (L-NAME, n ϭ 5; ANG II, n ϭ 7) and A1 ϩ/ϩ mice (L-NAME, n ϭ 5; ANG II, n ϭ 7). The telemetric measurements were conducted continuously under control conditions for 3 days and then continuously with L-NAME (A-C) or ANG II (D-F). Top: absolute blood pressure changes with L-NAME (A) and ANG II (D). Middle: as basal blood pressure was somewhat higher in A1 Ϫ/Ϫ than in A1 ϩ/ϩ mice, relative changes with L-NAME (B) and ANG II (E) compared with baseline are shown. Bottom: mean blood pressure levels during the control periods, and during treatment with L-NAME (C) or ANG II (F) are shown. Values are means Ϯ SE. *P Ͻ 0.05, vs. control (C) period (same genotype). #P Ͻ 0.05 vs. A ϩϩ mice (same period).
II (10 Ϫ12 to 10 Ϫ6 mol/l; each dose applied for 2 min). L-NAME (10 Ϫ4 mol/l), applied for 15 min, constricted afferent arterioles significantly more in A 1 ϩ/ϩ (14%) than in A 1 Ϫ/Ϫ mice (5%) (Fig. 4A) . During NOS inhibition with L-NAME the contractile response to ANG II was enhanced in A 1 ϩ/ϩ mice (maximal contraction 51%), but was not significantly changed in afferent arterioles of A 1 Ϫ/Ϫ mice (maximal contraction 21%) (Fig. 3B) .
EFFECT OF TEMPOL TREATMENT ON L-NAME AND ANG II-INDUCED CONTRACTIONS. To investigate the role of O 2 Ϫ for the differences in L-NAME and ANG II-induced arteriolar contraction, vessels were treated with L-NAME (10 Ϫ4 mol/l) and tempol (10 Ϫ4 mol/l) for 15 min before, and during treatment with ANG II (10 Ϫ12 to 10 Ϫ6 mol/l; each dose applied for 2 min). Ϫ/Ϫ (n ϭ 8) and A1 ϩ/ϩ mice (n ϭ 8). B: effect of L-NAME (10 Ϫ4 mol/l) on ANG II concentration response in arterioles of nontreated A1 Ϫ/Ϫ (n ϭ 6) and A1 ϩ/ϩ mice (n ϭ 6). C: effect of tempol (10 Ϫ4 mol/l) on L-NAME (10 Ϫ4 mol/l) and ANG II concentration response in arterioles of nontreated A1 Ϫ/Ϫ (n ϭ 6) and A1 ϩ/ϩ mice (n ϭ 8). Control period in B and C represents the baseline following L-NAME or tempol ϩ L-NAME pretreatment for 15 min, respectively. Values are presented as mean Ϯ SE. *P Ͻ 0.05 compared with A1 ϩ/ϩ mice.
Simultaneous treatment with tempol, attenuated the contractile response to L-NAME (6%) in A 1 ϩ/ϩ , but had no significant effect in A 1 Ϫ/Ϫ mice (6%) (Fig. 4B) . During NOS inhibition with L-NAME, tempol attenuated the contractile response to ANG II in A 1 ϩ/ϩ mice (maximal contraction 24%), but had no effect in A 1 Ϫ/Ϫ mice (maximal contraction 19%). In the presence of tempol, the renal microvascular responses to ANG II and L-NAME were only different between genotypes at the highest concentration with ANG II (Fig. 3C) .
Arteriolar contractions in mice with prolonged L-NAME treatment. EFFECT OF L-NAME TREATMENT ON ANG II-INDUCED CONTRACTIONS. Isolated vessels were treated with L-NAME (10 Ϫ4 mol/l) for 15 min before and during treatment with ANG II (10 Ϫ12 to 10 Ϫ6 mol/l; each dose applied for 2 min) in the same fashion as described above. Chronic L-NAME treatment for 10 days did not significantly change the arteriolar responses to acute L-NAME treatment for 15 min [(A 1 Ϫ/Ϫ 6%), (A 1 ϩ/ϩ 11%)] (Fig. 5A ) compared with nontreated mice (Fig. 4A) . Compared with nontreated mice (Fig. 3B) , the maximal contraction to ANG II during simultaneous NOS inhibition with L-NAME tended to be enhanced in A 1 ϩ/ϩ mice (56%, P ϭ 0.07), but was not changed in afferent arterioles of A 1 Ϫ/Ϫ mice (21%) (Fig. 6A) .
Arteriolar contractions in mice with prolonged ANG II treatment. EFFECT OF L-NAME TREATMENT ON ANG II-INDUCED CONTRACTIONS. Isolated vessels were treated with L-NAME (10 Ϫ4 mol/l) for 15 min before and during treatment with ANG II (10 Ϫ12 to 10 Ϫ6 mol/l; each dose applied for 2 min) in the same fashion as described above. Chronic ANG II treatment for 10 days did not significantly change the maximal arteriolar responses to L-NAME (15 min) (Fig. 5B ) compared with nontreated mice (Fig. 4A) . Compared with nontreated mice (Fig. 3B ) the maximal contraction to ANG II during simultaneous NOS inhibition with L-NAME was enhanced in A 1 ϩ/ϩ mice (58%), but was not changed in afferent arterioles of A 1 Ϫ/Ϫ mice (19%) (Fig. 6B ).
Arteriolar contractions in nontreated mice. EFFECT OF NOREPINEPHRINE. To investigate whether decreased vascular reactivity is a general phenomenon in A 1
Ϫ/Ϫ mice, arteriolar responses were studied using another vasoconstrictor without known interactions with adenosine receptors. Concentration response curves were obtained by cumulative application of norepinephrine (10 Ϫ12 to 10 Ϫ4 mol/l; each dose applied for 2 min). Maximal contraction to norepinephrine was similar between genotypes (Fig. 7) . Interestingly, the sensitivity to norepinephrine was slightly lower in A 1 Ϫ/Ϫ (Ϫlog EC50: 5.59 Ϯ 0.03 mol/l) than in A 1 ϩ/ϩ mice (Ϫlog EC50: 5.78 Ϯ 0.06 mol/l) (P Ͻ 0.05).
Plasma Analysis
L-arginine, ADMA, and SDMA. A recent study suggested that elevated levels of dimethylarginines could be secondary to the early development of oxidative stress, associated with the development of hypertension (26) . The plasma levels of L-arginine, ADMA, and SDMA are shown in Table 3 . ADMA and SDMA levels were similar in nontreated A 1 Ϫ/Ϫ and A 1 ϩ/ϩ mice. Chronic L-NAME treatment did not significantly influence ADMA, but SDMA levels were higher in A 1 ϩ/ϩ mice. Chronic ANG II treatment was associated with higher ADMA and SDMA levels in A 1 ϩ/ϩ compared with A 1 Ϫ/Ϫ mice. No significant differences were observed for L-arginine between A 1 Ϫ/Ϫ and A 1 ϩ/ϩ mice. MDA. The MDA levels were not different between nontreated A 1 Ϫ/Ϫ and A 1 ϩ/ϩ mice (Fig. 8) . However, chronic treatment with L-NAME or ANG II was associated with higher MDA levels in A 1 ϩ/ϩ compared with A 1 Ϫ/Ϫ mice.
Gene Expression Analysis of Renal Cortex
Adenosine and ANG II receptors, NOS isoforms, and NADPH oxidases. Real-time PCR analysis showed that cortical endothelial NOS (eNOS) and neuronal NOS (nNOS) levels were lower in nontreated A 1 Ϫ/Ϫ mice compared with A 1 ϩ/ϩ mice. However, except from the anticipated difference in A 1 expression, there were no differences in NADPH oxidase isoforms/subunits or ANG II and adenosine receptors between genotypes (Fig. 9) . Changes in gene expression with chronic L-NAME or ANG II treatments compared with nontreated mice are summarized in Table 4 . Both eNOS and nNOS expression were increased in ANG II-treated A 1 Ϫ/Ϫ mice, but was not changed in A 1 ϩ/ϩ mice. Consistent with higher levels of MDA in chronically treated A 1 ϩ/ϩ mice, L-NAME and ANG II treatments were associated with a greater upregulation in NADPH oxidase isoforms/subunits compared with A 1 Ϫ/Ϫ mice.
DISCUSSION
The balance between ROS and NO concentrations in the juxtaglomerular apparatus importantly modulate preglomerular resistance. Reduced NO bioavailability (49, 59) or elevated ANG II (2, 32, 42, 54) and ROS levels (30, 56) may sensitize TGF and have been associated with hypertension during chronic NOS inhibition (34) , in Milan hypertensive rats, in spontaneously hypertensive rats (48, 55) , and in hydronephrotic animals (5). To study the role played by adenosine A 1 -receptors in the development of hypertension in models with reduced NO or elevated ANG II levels, we used adenosine A 1 Ϫ/Ϫ and A 1 ϩ/ϩ mice. Our findings show that A 1 -receptor deficiency was associated with blunted arteriolar and blood pressure responses to L-NAME and ANG II treatment. The decreased vascular reactivity in A 1 Ϫ/Ϫ mice was not a general phenomenon, as arteriolar responses to both KCl and norepinephrine were similar to wild-types. Although further mechanistic studies are required, our results (as discussed below) suggest that changes in NO and ROS signaling contribute to the different responses between genotypes. 5 . Afferent arteriolar contractions to L-NAME in mice with prolonged L-NAME or ANG II treatment. Effect of L-NAME (10 Ϫ4 mol/l) on diameters of isolated and perfused afferent arteriolar from chronic L-NAME-treated (10 days) A1 Ϫ/Ϫ (n ϭ 8) and A1 ϩ/ϩ mice (n ϭ 8) (A) and chronic ANG II-treated (10 days) A1 Ϫ/Ϫ (n ϭ 6) and A1 ϩ/ϩ mice (n ϭ 6) (B). Values are means Ϯ SE. *P Ͻ 0.05 compared with A1 ϩ/ϩ mice.
In the kidney, both A 1 -and A 2--receptors are widely expressed in preglomerular vessels (23, 28, 51, 53) . The renal afferent arterioles exhibit a biphasic response to adenosine, with A 1 -mediated vasoconstriction and A 2 -mediated vasodilation (14, 28) . In afferent arterioles from A 1 -deficient mice or during pharmacological inhibition of A 1 -receptors, adenosine only produces vasodilatation (28) . Recent studies have demonstrated that A 2 -receptors attenuate TGF responses by counteracting the effects of A 1 -receptors (10, 11) . Together these findings show that A 2 -receptors buffer A 1 -induced vasoconstriction in preglomerular vessels and thus contribute to regulation of renal hemodynamics and blood pressure. There is considerable evidence for a synergic interaction between ANG II and adenosine in regulation of preglomerular resistance (17) . In isolated and perfused afferent arterioles, a low concentration of adenosine significantly enhanced ANG II-mediated contrac- Fig. 6 . Afferent arteriolar contractions to ANG II in mice with prolonged L-NAME or ANG II treatment. Effect of L-NAME (10 Ϫ4 mol/l) on ANG II concentration response in arterioles of chronic L-NAME-treated (10 days) A1 Ϫ/Ϫ (n ϭ 8) and A1 ϩ/ϩ mice (n ϭ 8) (A) and chronic ANG II-treated (10 days) A1 Ϫ/Ϫ (n ϭ 6) and A1 ϩ/ϩ mice (n ϭ 6) (B). Control period represents the baseline following L-NAME pretreatment for 15 min. Values are means Ϯ SE. *P Ͻ 0.05 compared with A1 ϩ/ϩ mice. tion, which was blocked by A 1 -receptor inhibition (28) . ANG II may elevate interstitial/tissue levels of adenosine in the kidney via increased release or reduced metabolism of adenosine (15, 19) . Franco et al. (15) demonstrated twofold higher adenosine levels with ANG II and that enhanced renal vasoconstriction in ANG II-treated rats was reverted by A 1 -receptor inhibition. In the present study, it is suggested that ANG II-mediated adenosine release is associated with opposite effects between genotypes. In A 1 ϩ/ϩ mice, elevated adenosine levels may enhance arteriolar contraction, but in A 1 -deficient mice this would only activate A 2 -receptors, and thus attenuate the contractile response to ANG II. Moreover, NO produced in the juxtaglomerular apparatus may attenuate the contractile responses via direct actions on vascular muscle cells (7, 10) or indirectly via scavenging of ROS (25, 30) .
Oxidative stress implies imbalance between ROS and NO bioavailability and has been linked to development of hypertension and cardiovascular disease. Both ANG II treatment and NOS inhibition are associated with oxidative stress in the kidney, which may increase preglomerular responses and lead to hypertension (9, 58) . During chronic L-NAME or ANG II treatments, the arteriolar contraction to ANG II and L-NAME was enhanced in A 1 ϩ/ϩ mice, but not changed in A 1 Ϫ/Ϫ mice. In a previous study we showed that pretreatment with ANG II sensitized arteriolar contraction in wild types, but did not alter ANG II responses in Nox2-deficient mice (7) . Activation of G protein-coupled receptors, including ANG II type-I receptors (AT 1 ), may stimulate NADPH oxidases and hence increase ROS formation. However, a relationship between adenosine and NA-DPH oxidase signaling has only been partially elucidated. In vitro and in vivo studies have shown that oxidative stress may activate ecto-5=-nucleotidase and increase adenosine production in the kidney (12) , whereas NO may inhibit ecto-5=-nucleotidase activity and reduce A 1 activation (40) . This suggests that ROS and NO, in opposite direction, may influence adenosine production and hence renal hemodynamics.
In smooth muscle cells, oxidative stress increased A 1 -receptor expression by activation of NF-B (33) . Activation of NADPH oxidases by G protein-coupled receptors is a widely observed event, although the precise pathways are only partially understood. AT 1 -receptors may stimulate NADPH oxidase activity and ROS production via protein kinase C (PKC)-, phospholipase C (PLC)-and phospholipase D (PLD)-dependent mechanisms (39) . Similar to ANG II, adenosine may stimulate PKC, PLC, and PLD signaling via A 1 -receptor activation (18) . In addition, A 1 -receptors may act synergistically with other G protein-coupled receptors and ligand-gated receptors to increase intracellular calcium levels (20, 21) . Interestingly, a recent study demonstrated that prooxidant stressorinduced elevations in ROS and intracellular calcium levels were more pronounced in primary cells from A 1 ϩ/ϩ compared with A 1 Ϫ/Ϫ mice (1). Together these findings indicate a positive feedback between A 1 -receptors and NADPH oxidase signaling. This notion was supported by several findings in the present study. First, the SOD-mimetic tempol attenuated arteriolar contractions to ANG II and L-NAME in A 1 ϩ/ϩ mice, but had no effect in A 1 -deficient mice. Second, chronic treatment Fig. 8 . A1-receptor deficiency protects against L-NAME and ANG II-induced oxidative stress. Plasma levels of malondialdehyde (MDA) in nontreated A1 Ϫ/Ϫ (n ϭ 8) and A1 ϩ/ϩ mice (n ϭ 10) (A), chronic L-NAME-treated (10 days) A1 Ϫ/Ϫ (n ϭ 7) and A1 ϩ/ϩ mice (n ϭ 7) (B), and chronic ANG II-treated (10 days) A1
Ϫ/Ϫ (n ϭ 5) and A1 ϩ/ϩ mice (n ϭ 5) (C). Values are means Ϯ SE. *P Ͻ 0.05 compared with A1 ϩ/ϩ mice. Ϫ/Ϫ (n ϭ 8) and A1 ϩ/ϩ mice (n ϭ 10), chronic L-NAME-treated (10 days) A1 Ϫ/Ϫ (n ϭ 6) and A1 ϩ/ϩ mice (n ϭ 7), and chronic ANG II-treated (10 days) A1 Ϫ/Ϫ (n ϭ 6) and A1 ϩ/ϩ mice (n ϭ 6). *P Ͻ 0.05 compared with A1 Ϫ/Ϫ mice; #P Ͻ 0.05 compared with nontreated mice of same genotype.
with L-NAME or ANG II increased plasma levels of oxidative stress marker in A 1 ϩ/ϩ but not in A 1 Ϫ/Ϫ mice. Third, elevated levels of dimethylarginines have been associated with ANG II infusion and oxidative stress and may contribute to renal and cardiovascular disease (31, 35) . In our study, both ADMA and SDMA levels were higher in ANG II-treated A 1 ϩ/ϩ than in A 1 Ϫ/Ϫ mice. Finally, elevation in several NADPH oxidase isoforms/subunits was observed in chronically treated A 1 ϩ/ϩ but not in A 1 Ϫ/Ϫ mice. In addition to a blunted arteriolar response to ANG II, A 1 Ϫ/Ϫ mice displayed reduced contraction to L-NAME compared with A 1 ϩ/ϩ mice. Basal tone and arteriolar responses to a NOS inhibitor depend on both ROS and NO formation. Simultaneous treatment with tempol attenuated L-NAME-induced contractions in A 1 ϩ/ϩ but did not influence arteriolar responses in A 1 Ϫ/Ϫ mice. This indicates that during basal conditions, preglomerular tone of A 1 -deficient mice is less dependent on NO production. Also compatible with this hypothesis was the finding that arteriolar diameter in nontreated A 1 Ϫ/Ϫ mice was somewhat larger despite lower expression of nNOS and eNOS.
Chronic ANG II treatment increased expression of constitutive NOS isoforms only in A 1 Ϫ/Ϫ mice, which may balance any elevation in ROS formation and hence maintain low arteriolar reactivity.
In conclusion, the present study provides evidence that adenosine A 1 -receptors enhance preglomerular responses during NO inhibition and ANG II treatment. Interruption of A 1 -receptor signaling blunts L-NAME and ANG II-induced hypertension and may reflect reduced responsiveness of afferent arterioles. Mechanistically, A 1 -receptors are suggested to augment oxidative stress in conditions with impaired NOS function and elevated ANG II levels.
Perspectives and Significances
Oxidative stress is implicated in the pathogenesis of renal and cardiovascular disease. Increased ROS and/or decreased NO formation may contribute to development of hypertension by sensitizing TGF and preglomerular reactivity. In the present study, A 1 -receptor-deficient mice that lack functional TGF displayed attenuated arteriolar and blood pressure responses to ANG II and L-NAME treatment. Although further mechanistic studies are required, our findings that indicate the regulation of ROS and NO signaling is different between A 1 ϩ/ϩ and A 1 Ϫ/Ϫ mice contribute to the different responses. Imbalance between A 1 and A 2 -receptor signaling, in favor of the former, enhances TGF (11, 16, 36, 41) and preglomerular responses (14, 22, 28) that may promote development of hypertension. This hypothesis is supported by findings that A 2 -deficient mice are hypertensive (29) and that A 1 -receptor inhibition attenuates hypertension in spontaneously hypertensive rats and Dahl salt-sensitive rats (27, 50) . Therefore, treatment strategies that target A 1 -or A 2 -receptor signaling in the kidney may become useful in preventing adverse renal and cardiovascular outcomes. Fold changes with chronic L-NAME or ANG II treatment (10 days) compared with nontreated controls. Adenosine receptors (A1, A2A, A2B, A3); NOS isoforms (eNOS, iNOS, nNOS); ANG II receptors (AT1A, AT1B); and NADPH oxidase isoforms/subunits (NOX1, NOX2, NOX4, p22phox, p47phox, p67phox) in the renal cortex of A1 ϩ/ϩ and A1 Ϫ/Ϫ mice. NOS, nitric oxide synthase; eNOS, endothelial NOS; iNOS, inducible NOS; nNOS, neuronal NOS. *P Ͻ 0.05 compared to control of same genotype.
